203 related articles for article (PubMed ID: 33526511)
21. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
22. Mouse models in the study of the Ets family of transcription factors.
Bartel FO; Higuchi T; Spyropoulos DD
Oncogene; 2000 Dec; 19(55):6443-54. PubMed ID: 11175360
[TBL] [Abstract][Full Text] [Related]
23. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
[TBL] [Abstract][Full Text] [Related]
24. The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents.
Spriano F; Chung EYL; Gaudio E; Tarantelli C; Cascione L; Napoli S; Jessen K; Carrassa L; Priebe V; Sartori G; Graham G; Selvanathan SP; Cavalli A; Rinaldi A; Kwee I; Testoni M; Genini D; Ye BH; Zucca E; Stathis A; Lannutti B; Toretsky JA; Bertoni F
Clin Cancer Res; 2019 Aug; 25(16):5167-5176. PubMed ID: 31182435
[TBL] [Abstract][Full Text] [Related]
25. An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.
Schafer CM; Gurley JM; Kurylowicz K; Lin PK; Chen W; Elliott MH; Davis GE; Bhatti F; Griffin CT
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26494-26502. PubMed ID: 33020273
[TBL] [Abstract][Full Text] [Related]
26. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
27. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
28. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene.
Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ
Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ
Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142
[TBL] [Abstract][Full Text] [Related]
30. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
[TBL] [Abstract][Full Text] [Related]
31. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
[TBL] [Abstract][Full Text] [Related]
32. Ets up-regulates MET transcription.
Gambarotta G; Boccaccio C; Giordano S; Andŏ M; Stella MC; Comoglio PM
Oncogene; 1996 Nov; 13(9):1911-7. PubMed ID: 8934537
[TBL] [Abstract][Full Text] [Related]
33. Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
Soldatenkov VA; Trofimova IN; Rouzaut A; McDermott F; Dritschilo A; Notario V
Oncogene; 2002 Apr; 21(18):2890-5. PubMed ID: 11973649
[TBL] [Abstract][Full Text] [Related]
34. SRE elements are binding sites for the fusion protein EWS-FLI-1.
Magnaghi-Jaulin L; Masutani H; Robin P; Lipinski M; Harel-Bellan A
Nucleic Acids Res; 1996 Mar; 24(6):1052-8. PubMed ID: 8604338
[TBL] [Abstract][Full Text] [Related]
35. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.
Kovar H; Aryee DN; Jug G; Henöckl C; Schemper M; Delattre O; Thomas G; Gadner H
Cell Growth Differ; 1996 Apr; 7(4):429-37. PubMed ID: 9052984
[TBL] [Abstract][Full Text] [Related]
36. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
37. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
[TBL] [Abstract][Full Text] [Related]
38. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
39. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Liu F; Cao J; Wu J; Sullivan K; Shen J; Ryu B; Xu Z; Wei W; Cui R
J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
[TBL] [Abstract][Full Text] [Related]
40. EWS/ETS fusions activate telomerase in Ewing's tumors.
Takahashi A; Higashino F; Aoyagi M; Yoshida K; Itoh M; Kyo S; Ohno T; Taira T; Ariga H; Nakajima K; Hatta M; Kobayashi M; Sano H; Kohgo T; Shindoh M
Cancer Res; 2003 Dec; 63(23):8338-44. PubMed ID: 14678994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
